Biotech Sector Performance in April: Gilead Sciences Rising

Some work-related travel kept me from posting this yesterday, but here's the April performance of the biotech sector:


IBB Chart
IBB data by YCharts

Not pretty, but then, you already know that. Rising off the mid-month low is something to be happy about, I guess.

Here's where we stand year to date:

IBB Chart
IBB data by YCharts

I've noted previously the correlation between the declines in Gilead Sciences (GILD) and the broader biotech sector. April broke that trend, which is an encouraging sign that investors are perhaps starting to differentiate between quality stocks and over-valued garbage. 


IBB Chart
IBB data by YCharts

The April performance of big-cap biotech stocks:


IBB Chart

 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

More from Investing

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Never Buy Stocks Based on Unusual Call Activity: Doug Kass Insider

Wells Fargo to Face $1 Billion in Fines Over Car-Insurance Probe

Wells Fargo to Face $1 Billion in Fines Over Car-Insurance Probe

Starbucks Got a Few Things Wrong in Managing Crisis, Expert Says

Starbucks Got a Few Things Wrong in Managing Crisis, Expert Says

Mattel Names Ynon Kreiz CEO to Replace Georgiadis

Mattel Names Ynon Kreiz CEO to Replace Georgiadis

Will Tesla Stock Tumble 33% to $195?

Will Tesla Stock Tumble 33% to $195?